共 122 条
[1]
Aalbersberg EA(2022)Quality control of [177Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery EJNMMI Radiopharm Chem 7 24-495
[2]
Cao TT(2013)PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions Eur J Nucl Med Mol Imag 40 486-1705
[3]
Geluk-Jonker MM(2015)The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions J Nucl Med 56 1697-4270
[4]
Hendrikx JJMA(2022)177Lu-PSMA-I&T radioligand therapy for treating metastatic castration-resistant prostate cancer: a single-centre study in East Asians Front Oncol 12 835956-3276
[5]
Afshar-Oromieh A(2022)Production and quality control of [177Lu]Lu-PSMA-I&T: development of an investigational medicinal product dossier for clinical trials Molecules 27 4143-926
[6]
Malcher A(2020)EANM guideline on the validation of analytical methods for radiopharmaceuticals EJNMMI Radiopharm Chem 5 7-69
[7]
Eder M(2022)Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up Eur J Nucl Med Mol Imaging 49 4262-9
[8]
Eisenhut M(2022)Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer Eur J Nucl Med Mol Imag 49 3269-895
[9]
Linhart HG(2019)Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer Eur Urol 75 920-73
[10]
Hadaschik BA(2022)Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [177Lu]Lu-PSMA EJNMMI Radiopharm Chem 7 29-1207